A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients
Launched by MYLAN BERTEK PHARMACEUTICALS · Sep 12, 2005
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
This study was a multi-center, multi-national, randomized, double-blind, parallel group, placebo-controlled study of nebivolol over a range of doses in patients with mild to moderate hypertension. The study consisted of 2 phases: screening/washout/single-blind placebo run-in and 2) randomization/double-blind treatment. Patients had 7 scheduled clinic visits during the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • An average sitting diastolic blood pressure of greater then or equal to 95 mmHg and less then or equal to 109 mmHg at baseline
- Exclusion Criteria:
- • Recent myocardial infarction or stroke
- • Secondary hypertension
- • Contraindications to beta-blocker therapy or discontinuation of prior antihypertensive agents
- • Pregnancy, nursing or women of childbearing age not using appropriate contraception
About Mylan Bertek Pharmaceuticals
Mylan Bertek Pharmaceuticals, a subsidiary of Viatris, is a leading global healthcare company dedicated to providing access to high-quality medicines for patients around the world. With a strong focus on research and development, Mylan Bertek Pharmaceuticals specializes in the formulation and commercialization of generic and specialty pharmaceuticals across a wide range of therapeutic areas. The company is committed to advancing healthcare through innovative solutions and rigorous clinical trials, ensuring that its products meet the highest standards of safety and efficacy. By leveraging its extensive expertise and global reach, Mylan Bertek Pharmaceuticals strives to enhance patient outcomes and improve quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Morgantown, West Virginia, United States
Patients applied
Trial Officials
Betty S. Riggs, MD, MBA
Study Director
Mylan Pharmaceuticals Inc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials